Chronic pain represents a major challenge in internal medicine due to its persistent nature, heterogeneous presentation, and frequent dissociation from identifiable tissue damage. Contemporary evidence indicates that chronic pain should be conceptualized as a multisystem condition sustained by interacting mechanisms of peripheral sensitization, neuropathic remodeling, and central sensitization, rather than as a linear extension of acute nociception. This narrative integrative review synthesizes key findings from pain neuroscience, clinical research, and contemporary classification systems to examine how these mechanisms contribute to pain persistence, symptom amplification, and functional impairment. The analysis highlights the clinical relevance of pain phenotyping—nociceptive, neuropathic, nociplastic, and mixed—using observable clinical features commonly encountered in internal medicine practice. Patterns such as widespread pain, disproportionate symptom intensity, sleep disturbance, fatigue, cognitive complaints, and autonomic manifestations are discussed as indicators of central-dominant mechanisms. The review further explores how differential therapeutic responsiveness across phenotypes supports a mechanism-based approach to management, emphasizing the limitations of uniform analgesic strategies and the value of interdisciplinary care, including pharmacologic modulation, rehabilitation, and pain education. By integrating mechanistic understanding with diagnostic reasoning, this review provides an educational framework aimed at improving clinical decision-making in internal medicine. Recognizing chronic pain as a condition with modifiable neurobiological drivers supports more individualized, effective, and patient-centered care across diverse healthcare settings.

Insulin resistance represents a critical stage in the development of type 2 diabetes mellitus (T2DM), frequently preceding clinical diagnosis by several years. Increasing evidence indicates that the gut–pancreas axis plays a central role in metabolic regulation through complex interactions between intestinal microbiota, microbial metabolites, inflammatory signaling, and pancreatic endocrine function. This review synthesizes current scientific evidence on the contribution of the gut–pancreas axis to insulin resistance, with particular emphasis on emerging microbiome-related biomarkers with potential predictive value for T2DM. A structured narrative review of peer-reviewed international literature was conducted, integrating experimental, observational, metagenomic, and interventional studies addressing gut microbiota composition, functional metabolic outputs, inflammatory pathways, and biomarker development. The findings indicate that functional microbial products, especially short-chain fatty acids, along with metabolic inflammation and endotoxemia-related mechanisms, are consistently associated with impaired insulin sensitivity. Metagenomic signatures and barrier-related interactions further support a systems-level role of the gut microbiome in metabolic dysregulation, while dietary and microbiota-based interventions demonstrate the modifiability of these pathways. Collectively, the evidence supports the gut–pancreas axis as a biologically coherent and clinically relevant framework for early risk stratification of insulin resistance. Integrative biomarker models combining microbial, inflammatory, and conventional metabolic indicators may enhance early prediction and inform preventive strategies across diverse populations.

Cardiorenal syndrome (CRS) represents a complex bidirectional interaction between the cardiovascular and renal systems in which dysfunction of one organ may induce or worsen dysfunction of the other. The increasing global prevalence of heart failure, chronic kidney disease, hypertension, obesity, and diabetes mellitus has significantly contributed to the growing clinical and epidemiological burden of CRS. This review aimed to analyze the principal pathophysiological mechanisms, diagnostic approaches, and contemporary therapeutic strategies associated with cardiorenal syndrome through an evidence-based analysis of current scientific literature. The study was developed as a narrative and analytical review using scientific evidence obtained from internationally recognized databases, including PubMed, Scopus, Web of Science, and high-impact journals in nephrology, cardiology, and internal medicine. The analysis focused on hemodynamic alterations, neurohormonal activation, venous congestion, inflammatory pathways, endothelial dysfunction, oxidative stress, diagnostic biomarkers, pharmacological therapies, and multidisciplinary management approaches. The reviewed evidence demonstrated that CRS is a multifactorial systemic condition involving complex interactions between cardiac and renal dysfunction. Venous congestion, activation of the renin–angiotensin–aldosterone system, sympathetic nervous system stimulation, chronic inflammation, and endothelial injury were identified as major contributors to disease progression. Biomarkers such as NT-proBNP, cystatin C, NGAL, and KIM-1 showed important diagnostic and prognostic value, although integrated clinical evaluation remains essential. Contemporary therapeutic strategies, particularly sodium-glucose cotransporter-2 inhibitors, demonstrated substantial cardiovascular and renal protective effects. Multidisciplinary care models were also associated with improved patient outcomes and optimization of long-term management. In conclusion, cardiorenal syndrome should be understood as a highly dynamic and multisystemic condition requiring integrated cardiovascular and renal assessment. Early diagnosis, evidence-based therapy, preventive medicine, and multidisciplinary collaboration remain fundamental for improving prognosis and reducing the global burden associated with CRS.

Cardiorenal syndrome associated with type 2 diabetes mellitus has emerged as a major global health challenge due to its increasing prevalence, complex pathophysiology, and significant impact on morbidity and mortality. The interaction between cardiovascular disease, chronic kidney disease, and metabolic dysfunction creates a bidirectional cycle of organ damage mediated by inflammation, oxidative stress, endothelial dysfunction, neurohormonal activation, and fibrosis. This review analyzes current evidence regarding the mechanisms linking diabetes with cardiovascular and renal deterioration, emphasizing the concept of the cardiorenal-metabolic continuum. A comprehensive review of contemporary literature was conducted using international scientific databases and clinical practice guidelines. The findings indicate that recent therapeutic advances, particularly sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists, have significantly improved cardiovascular and renal outcomes while reducing disease progression and hospitalization rates. Despite these advances, substantial challenges remain regarding early diagnosis, treatment accessibility, therapeutic implementation, and healthcare disparities. These challenges are especially relevant in Latin American countries, including Mexico, Colombia, and Ecuador, where the burden of diabetes and chronic kidney disease continues to rise. Current evidence supports the adoption of integrated multidisciplinary approaches focused on early detection, comprehensive risk assessment, and evidence-based therapeutic interventions. The transition from organ-centered management toward a cardiorenal-metabolic model represents a fundamental paradigm shift that may contribute to improved patient survival, preservation of organ function, and enhanced quality of life.

Cardiomyopathies constitute a heterogeneous group of myocardial disorders that frequently remain clinically silent until advanced stages, limiting opportunities for early intervention and prevention of adverse outcomes. Although the 12-lead electrocardiogram (ECG) is one of the most accessible diagnostic tools in cardiovascular care, its conventional interpretation has limited sensitivity for detecting early or subclinical myocardial disease. In recent years, deep-learning approaches have enabled a paradigm shift in ECG analysis by allowing the extraction of complex and subtle signal patterns associated with underlying structural and functional cardiac abnormalities. This review synthesizes current evidence on deep-learning–based ECG algorithms for the silent detection of cardiomyopathies, with particular emphasis on hypertrophic cardiomyopathy and subclinical ventricular dysfunction. The analysis highlights methodological strategies, reference standards, and validation approaches used across key studies, as well as their potential clinical and educational implications. The findings suggest that deep-learning ECG analysis can function as an effective screening and risk-stratification tool, facilitating earlier identification of individuals who may benefit from confirmatory imaging and specialist evaluation. This approach is especially relevant for healthcare systems in Mexico, Colombia, and Ecuador, where access to advanced diagnostic resources may be limited. Continued research focusing on external validation, population-specific calibration, and real-world implementation is essential to ensure safe and effective integration into clinical practice.

Chronic kidney disease (CKD) without diabetes mellitus has become an increasingly recognized clinical entity whose progression cannot be explained exclusively by traditional hemodynamic mechanisms. Growing evidence indicates that endocrine dysregulation, metabolic remodeling, mitochondrial dysfunction, chronic inflammation, oxidative stress, and altered communication between the kidney and other organ systems play fundamental roles throughout disease development and progression. The present review critically analyzes current scientific evidence regarding the endocrine and metabolic mechanisms involved in non-diabetic CKD, integrating findings from nephrology, endocrinology, and internal medicine while incorporating information relevant to Latin American populations. A narrative review based on the Scientific Method was conducted using high-quality publications retrieved from internationally recognized databases and clinical practice guidelines. The available evidence demonstrates that persistent activation of the renin–angiotensin–aldosterone system, disruption of the fibroblast growth factor 23–Klotho axis, impaired vitamin D metabolism, insulin resistance, obesity-related endocrine alterations, mitochondrial dysfunction, and gut–kidney interactions contribute substantially to renal fibrosis, progressive loss of kidney function, and cardiovascular complications. Contemporary therapeutic approaches, particularly sodium–glucose cotransporter-2 inhibitors, have significantly modified disease management by providing nephroprotective effects beyond glycemic control. Emerging biomarkers and precision medicine strategies also show considerable potential for improving early diagnosis, individualized risk assessment, and targeted therapeutic interventions. Nevertheless, additional multicenter studies, particularly involving underrepresented regions such as Latin America, remain necessary to strengthen the current evidence base. Overall, non-diabetic CKD should be regarded as a complex multisystem disorder requiring an integrated clinical approach that combines endocrine, metabolic, cardiovascular, and nephrological perspectives to optimize patient outcomes.